- Home
- PRG vs TVTX Comparison
PRG vs TVTX Comparison
Compare PRG & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- TVTX
- Stock Information
- Founded
- PRG 2020
- TVTX 2008
- Country
- PRG United States
- TVTX United States
- Employees
- PRG N/A
- TVTX N/A
- Industry
- PRG Diversified Commercial Services
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRG Consumer Discretionary
- TVTX Health Care
- Exchange
- PRG Nasdaq
- TVTX Nasdaq
- Market Cap
- PRG 1.4B
- TVTX 1.5B
- IPO Year
- PRG N/A
- TVTX N/A
- Fundamental
- Price
- PRG $35.35
- TVTX $21.64
- Analyst Decision
- PRG Hold
- TVTX Strong Buy
- Analyst Count
- PRG 5
- TVTX 16
- Target Price
- PRG $37.20
- TVTX $34.53
- AVG Volume (30 Days)
- PRG 323.9K
- TVTX 1.9M
- Earning Date
- PRG 10-22-2025
- TVTX 10-30-2025
- Dividend Yield
- PRG 1.47%
- TVTX N/A
- EPS Growth
- PRG 109.72
- TVTX N/A
- EPS
- PRG 5.11
- TVTX N/A
- Revenue
- PRG $2,518,216,000.00
- TVTX $333,865,000.00
- Revenue This Year
- PRG $1.44
- TVTX $83.26
- Revenue Next Year
- PRG $3.56
- TVTX $43.19
- P/E Ratio
- PRG $6.91
- TVTX N/A
- Revenue Growth
- PRG 5.17
- TVTX 87.94
- 52 Week Low
- PRG $23.50
- TVTX $9.44
- 52 Week High
- PRG $50.28
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- PRG 66.25
- TVTX 78.22
- Support Level
- PRG $34.44
- TVTX $17.27
- Resistance Level
- PRG $35.47
- TVTX $19.57
- Average True Range (ATR)
- PRG 0.84
- TVTX 0.99
- MACD
- PRG 0.03
- TVTX 0.33
- Stochastic Oscillator
- PRG 79.64
- TVTX 88.44
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.